Fidelity Investments
KPTI icon

Fidelity Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Fidelity Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.7K Sell
665
-14
-2% -$107 ﹤0.01% 4964
2025
Q4 		$5K Hold
679
– – ﹤0.01% 4886
2025
Q3 		$4.44K Sell
679
-86
-11% -$463 ﹤0.01% 4811
2025
Q2 		$3.3K Buy
765
+238
+45% +$1.17K ﹤0.01% 4782
2025
Q1 		$1.97K Sell
527
-26,970
-98% -$230K ﹤0.01% 4879
2024
Q4 		$279K Buy
27,497
+2,849
+12% +$34.4K ﹤0.01% 3140
2024
Q3 		$307K Buy
24,648
+5,100
+26% +$63.4K ﹤0.01% 3046
2024
Q2 		$254K Buy
19,548
+1,294
+7% +$21.4K ﹤0.01% 2956
2024
Q1 		$413K Buy
18,254
+368
+2% +$6.45K ﹤0.01% 2788
2023
Q4 		$232K Buy
17,886
+123
+0.7% +$1.66K ﹤0.01% 2920
2023
Q3 		$357K Buy
17,763
+24
+0.1% +$539 ﹤0.01% 2721
2023
Q2 		$476K Buy
17,739
+10,073
+131% +$434K ﹤0.01% 2674
2023
Q1 		$447K Buy
7,666
+271
+4% +$13.4K ﹤0.01% 2728
2022
Q4 		$377K Sell
7,395
-78
-1% -$5.41K ﹤0.01% 2808
2022
Q3 		$612K Sell
7,473
-28
-0.4% -$2.09K ﹤0.01% 2726
2022
Q2 		$507K Sell
7,501
-97
-1% -$8.9K ﹤0.01% 2840
2022
Q1 		$840K Buy
+7,598
New +$947K ﹤0.01% 2823
2021
Q3 		– Hold
0
– – – 4722
2021
Q2 		– Sell
-5,281
Closed -$766K – 4591
2021
Q1 		$833K Sell
5,281
-5,426
-51% -$1.14M ﹤0.01% 2609
2020
Q4 		$2.49M Sell
10,707
-1,094
-9% -$254K ﹤0.01% 2358
2020
Q3 		$2.58M Sell
11,801
-33,226
-74% -$8.13M ﹤0.01% 2244
2020
Q2 		$12.8M Sell
45,027
-6,260
-12% -$1.85M ﹤0.01% 1723
2020
Q1 		$14.8M Buy
51,287
+9,167
+22% +$2.53M ﹤0.01% 1537
2019
Q4 		$12.1M Sell
42,120
-9,500
-18% -$2.06M ﹤0.01% 1784
2019
Q3 		$7.45M Sell
51,620
-18,253
-26% -$2.47M ﹤0.01% 1929
2019
Q2 		$6.28M Sell
69,873
-32,380
-32% -$2.6M ﹤0.01% 2024
2019
Q1 		$8.96M Sell
102,253
-22,756
-18% -$2.52M ﹤0.01% 1897
2018
Q4 		$17.6M Buy
125,009
+42,490
+51% +$7.17M ﹤0.01% 1609
2018
Q3 		$21.1M Sell
82,519
-20,160
-20% -$5.57M ﹤0.01% 1660
2018
Q2 		$26.2M Sell
102,679
-99,480
-49% -$24.6M ﹤0.01% 1601
2018
Q1 		$40.7M Sell
202,159
-63,377
-24% -$12.6M ﹤0.01% 1399
2017
Q4 		$38.2M Sell
265,536
-1,653
-0.6% -$265K ﹤0.01% 1423
2017
Q3 		$44M Sell
267,189
-21,133
-7% -$3.03M 0.01% 1361
2017
Q2 		$39.1M Hold
288,322
– – ﹤0.01% 1395
2017
Q1 		$55.5M Sell
288,322
-27,020
-9% -$4.34M 0.01% 1256
2016
Q4 		$44.5M Sell
315,342
-41,980
-12% -$5.68M 0.01% 1358
2016
Q3 		$52.2M Hold
357,322
– – 0.01% 1274
2016
Q2 		$36M Hold
357,322
– – ﹤0.01% 1418
2016
Q1 		$47.8M Hold
357,322
– – 0.01% 1265
2015
Q4 		$71M Buy
357,322
+211
+0.1% +$45.7K 0.01% 1111
2015
Q3 		$56.4M Buy
357,111
+163
+0% +$43.6K 0.01% 1195
2015
Q2 		$146M Buy
356,948
+11,654
+3% +$5.04M 0.02% 854
2015
Q1 		$159M Buy
345,294
+18,288
+6% +$7.88M 0.02% 801
2014
Q4 		$184M Buy
327,006
+56,403
+21% +$32M 0.02% 722
2014
Q3 		$142M Buy
270,603
+42,994
+19% +$24.3M 0.02% 810
2014
Q2 		$159M Buy
227,609
+71,209
+46% +$33.1M 0.02% 770
2014
Q1 		$72.5M Hold
156,400
– – 0.01% 1148
2013
Q4 		$53.8M Buy
+156,400
New +$43.2M 0.01% 1277

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Fidelity Investments's KPTI Position: Q1 2026 in Review

Fidelity Investments reduced its Karyopharm Therapeutics (KPTI) stake by 2.1% in Q1 2026, selling an estimated $107 and leaving 665 shares worth $3.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4964.

Fidelity Investments first reported a position in KPTI in Q4 2013 and has held it in 47 quarters since. The position peaked at $184M in Q4 2014. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Fidelity Investments held 665 shares of Karyopharm Therapeutics worth $3.7K as of Q1 2026.
  • Fidelity Investments sold 14 Karyopharm Therapeutics shares in Q1 2026, an estimated $107.
  • Karyopharm Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4964 holding.
  • Fidelity Investments first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 47 quarters since.
  • Fidelity Investments's Karyopharm Therapeutics position peaked at $184M in Q4 2014.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.